Research Communication: The Risk and Outcomes of Gastrointestinal Bleeding in Patients Using Warfarin or Direct Oral...

Area of Science:

• Gastroenterology
• Pharmacology
• Clinical Research

Background:

• Gastrointestinal bleeding (GIB) is a significant medical emergency.
• Anticoagulant medications, including vitamin K antagonists (e.g., warfarin) and direct oral anticoagulants (DOACs), are frequently used but pose risks.
• Understanding the impact of these medications on GIB outcomes is crucial for patient care.

Purpose of the Study:

• To investigate the association between anticoagulant use and patient outcomes in cases of upper and lower gastrointestinal bleeding.
• To compare the severity and mortality of GIB in patients taking anticoagulants versus those not on these medications.

Main Methods:

• Utilized the TriNetX global research database for patient data analysis.
• Included patients diagnosed with gastrointestinal bleeding.
• Employed propensity score matching to control for confounding variables such as age, sex, race, and comorbidities, comparing anticoagulated patients with non-anticoagulated patients.

Main Results:

• Patients on either DOACs or warfarin experienced more severe gastrointestinal bleeding compared to non-anticoagulated individuals.
• Mortality rates were significantly higher in patients taking anticoagulant medications, even after adjusting for comorbidities.
• Anticoagulated patients exhibited higher incidences of delayed endoscopy procedures.

Conclusions:

• Anticoagulant therapy is associated with increased severity and mortality in patients with gastrointestinal bleeding.
• The findings highlight the need for careful consideration of bleeding risks in patients requiring anticoagulation.
• Further research may inform strategies for managing GIB in anticoagulated populations.